GET DAILY SIGNALSMadrigal Pharmaceuticals (MDGL) Turns Profitable on +50% Rezdiffra Sales Growth
Key Takeaways
- Madrigal reported third-quarter 2026 net sales of $431.3 million, up 50% year over year, driven entirely by its lead therapy Rezdiffra.
- The company delivered net income of $55.4 million, or $1.90 per basic share ($1.83 diluted), marking its first-ever profitable quarter versus a net loss of $114.2 million a year earlier.
- Year-to-date Rezdiffra net sales crossed $1 billion, reaching blockbuster status less than three years after launch, with more than 55,850 patients actively on therapy at quarter end.
- Operating cash flow was positive for a second consecutive quarter, and cash and marketable securities totaled $961.8 million.
- Management narrowed its F4c (compensated cirrhosis) outcomes readout to late 2027 and unveiled a second Phase 3 trial, MAESTRO-CSPH, expected to begin in the first half of 2027.
- For more information about the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for MDGL.
- Explore Trending AI Robots to discover AI-driven trading strategies and market signals.
Why This Quarter Matters for Madrigal
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet need. Its lead drug, Rezdiffra (resmetirom), became the first therapy approved in both the U.S. and Europe for MASH with moderate to advanced fibrosis. The commercial uptake has ranked among the stronger specialty launches in recent biotech history. This quarter stands out because it marks the shift from years of equity-financed operations to the company's first profitable period. The numbers also provide a clear view of prescriber adoption, patient growth, and market-access progress, which form the core of the long-term investment thesis.
Quarterly Results in Detail
For the third quarter ended September 30, 2026, Madrigal reported net sales of $431.3 million, up 50% from $287.3 million in the same period last year. Year-to-date sales reached $1.1 billion, moving Rezdiffra into blockbuster territory. Net income came in at $55.4 million, or $1.90 per basic share ($1.83 diluted), versus a net loss of $114.2 million, or $4.01 per share, a year earlier. The result exceeded forecasts that anticipated a loss and represented the first profitable quarter in the company's history.
Operating expenses fell to $375.3 million from $401.2 million, mainly due to a one-time $117.3 million upfront charge recorded in research and development last year. R&D expense dropped to $71.8 million from $174 million, while selling, general, and administrative expense increased to $265.7 million from $209.1 million as commercial efforts expanded. Management now expects 2026 gross-to-net to land at the low end of the mid-to-high 30s range and has guided R&D modestly lower than 2025 levels. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Views
Heading into the report, attention centered on whether Madrigal could maintain Rezdiffra's launch momentum and translate revenue growth into sustained profitability. The company delivered a positive earnings surprise, backed by the 50% year-over-year sales increase and active patients rising to more than 55,850. Some debate persists around slower year-over-year growth rates and potential 2027 pricing pressure from Medicare Part D contracts. Management noted that profitability could fluctuate in the near term due to investment timing and typical first-quarter seasonality, so investors are balancing short-term volatility against longer-term commercial progress.
What to Watch Going Forward
After this milestone quarter, several factors tied to Rezdiffra execution deserve close attention. Patient growth and prescriber depth remain central, as revenue depends on new starts and adherence in the approved F2-F3 population. Management views the U.S. F2-F3 MASH market as accelerating, with more than 30% growth expected in 2026, though gross-to-net pressure is likely to move toward the higher end of the range in 2027 as Medicare contracts take effect.
Expense control is another key area. SG&A is expected to rise in the fourth quarter, and the new MAESTRO-CSPH trial will add multi-year costs. With possible swings in and out of profitability, operating cash flow and the $961.8 million cash position will serve as important indicators of financial flexibility. From what I see, the pipeline offers longer-term upside. The MAESTRO-NASH OUTCOMES readout is now expected in late 2027, and the MAESTRO-CSPH study, focused on clinically significant portal hypertension, is slated to start in the first half of 2027. More than ten combination programs are outlined, including three Phase 2 trials planned for 2027.
AI Tools in My Research Process
When evaluating names like MDGL, I often turn to Tickeron’s AI-powered tools to cross-check technical patterns and fundamentals alongside traditional analysis. These resources help surface comparable names and highlight potential signals that might otherwise take longer to identify manually. In this case, the screener confirmed the relative strength in the biotech space without altering the core fundamental picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDGL's RSI Indicator is sitting in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MDGL entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.484) is normal, around the industry mean (3.051). P/E Ratio (-28.329) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology
Advertisement